Miscellaneous patents.
| Reference | Name of mushroom | Bioactive/Extract | Disease name(s) | Biological role | Formulation type |
|---|---|---|---|---|---|
| [168] | Psilocybe spp. | Psilocybin, psilocin, 4-hydroxytryptamine, [3-(2-dimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N,N-dimethyl-tryptamine, 4-hydroxy-N,N,N-trimethyltryptamine, [3-(2-methylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate, [3-(2-trimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate | Traumatic events: post-traumatic stress disorder (PTSD)Nicotine or alcohol addiction, anorexia, depression | Pathological conversion of short-term memory (STM) to long-term memory (LTM) by promoting disengagement of pathological LTM by a chemical agonist/antagonist shock | Controlled release fixed-dose combination with a cannabis-derived agent as a capsule/multi-layer tablet |
| [169] | Multiple species1 | Extract | Burns | Promotes cell regeneration by increasing the amount of collagen production, exhibits stronger antibacterial activity | Ointment, dressing agent, patch |
| [170] | Sparassis crispa | Extract | Dry eye syndrome | Promotes hyaluronic acid production and/or secretion in ocular keratocytes | Administered by oral route or as an eye drop |
| [171] | Multiple species2 | Extract | Bladder disease | Uropathic, analgesic, anti-inflammatory | Administered by oral, nasal, intravenous, intra-arterial, intramuscular, intraperitoneal, ocular, buccal, vaginal, rectal, subcutaneous, transdermal routes |
| [172] | Poria cocos | Extract | Chronic renal failure | Reduction of blood creatinine and urea nitrogen reduces the expression of Bax and Caspase-3 and up-regulates the expression of bcl-2, inhibiting apoptosis and delaying the progression of CRF | Granule, capsule, tablet, pill, or oral liquid |
| [173] | Agaricus blazei | Extract | Benign prostatic hyperplasia (BPH) | Inhibits 5-α-reductase, catalase, superoxide dismutase, interleukin-1 beta, cyclooxygenase-2 | Administered by oral, parenteral, inhalation, transplantation, and transdermal routes |
| [174] | Multiple species3 | Extract | Keloid scar | Inhibit the proliferation of keloid fibroblasts to eliminate or reduce the symptoms of keloids or eliminate scar tissue | Liposome structure with lipid layer and composite core layer |
| [175] | Multiple species4 | Extract | Post-acute sequelae severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) | Moderating a hyper immune response, destroying and removing the SARS-CoV-2 spike protein from the gut and body, detoxifying the body and the brain, replenishing key nutrients, mitigating depression and anxiety, and a regimen of physical and mental exercise | Oral administration |
| [176] | Wolfiporia extensa | Extract | Insomnia | Promotes sleep, improves sleep quality, and prolongs sleep time | Granule, ointment, oral liquid, capsule, tablet, or pill |
1: C. sinensis, H. erinaceus; 2: Agaricus spp., Agrocybe spp., Albatrellus spp., Amanita spp., Antrodia spp., Auricularia spp., Boletus spp., Calvatia spp., Cantharellus spp., Caripia spp., Clitocybe spp., Cordyceps spp., Cyathus spp., Daldinia spp., Dictyophora spp., Elaphomyces spp., Flammulina spp., Pomes spp., Fomitopsis spp., Funalia spp., Ganoderma spp., Geastrum spp., Grifola spp., Hericium spp., Inocybe spp., Inonotus spp., Lactarius spp., Lentinus spp., Lentinula spp., Leucopaxillus spp., Lyophyllum spp., Phellinus spp., Pholiota spp., and Pleurotus spp.; 3: F. velutipes, T. fuciformis; 4: I. obliquus, T. versicolor, H. erinaceus.
PB: Conceptualization, Investigation, Data curation, Methodology, Supervision, Writing—original draft, Writing—review & editing. AM: Conceptualization, Investigation, Data curation, Supervision, Writing—original draft, Writing—review & editing. SW: Formal analysis, Validation, Visualization. All authors read and approved the submitted version.
The authors declare that there are no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
© The Author(s) 2025.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.